When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

Theresa Wingrove net worth and biography

Theresa Wingrove Biography and Net Worth

SVP of ImmunoGen

Dr. Wingrove joined ImmunoGen in early 2011 with over twenty years of regulatory and clinical management experience in the healthcare industry. Before joining ImmunoGen, she was the vice president of regulatory and clinical affairs at Histogenics, where her responsibilities included authoring and gaining approval of a SPA for a Phase III trial for a novel biologic and other regulatory responsibilities in the US and Europe. Prior to that, she was the senior director of regulatory and clinical affairs at MediSpectra, where she was responsible for the full spectrum of regulatory support – from start of clinical testing through marketing approval – for a novel cancer diagnostic product. Prior to joining MediSpectra, Dr. Wingrove was at Pfizer-Infusaid for over ten years, during which time she executed the clinical and regulatory programs associated with the company’s combination products. She holds a BS in Biochemistry from Brown University and a doctorate in Biochemical Toxicology from the University of Rochester.

What is Theresa Wingrove's net worth?: The estimated net worth of Theresa Wingrove is at least $106,993.98 as of January 16th, 2024. Dr. Wingrove owns 3,426 shares of ImmunoGen stock worth more than $106,994 as of April 28th. This net worth estimate does not reflect any other investments that Dr. Wingrove may own. Additionally, Dr. Wingrove receives an annual salary of $548,210.00 as SVP at ImmunoGen. Learn More about Theresa Wingrove's net worth.
How old is Theresa Wingrove?: Dr. Wingrove is currently 66 years old. There are 4 older executives and no younger executives at ImmunoGen. Learn More on Theresa Wingrove's age.
What is Theresa Wingrove's salary?: As the SVP of ImmunoGen, Inc., Dr. Wingrove earns $548,210.00 per year. The highest earning executive at ImmunoGen is Mr. Mark Joseph Enyedy, President, CEO & Director, who commands a salary of $1,280,000.00 per year. Learn More on Theresa Wingrove's salary.
How do I contact Theresa Wingrove?: The corporate mailing address for Dr. Wingrove and other ImmunoGen executives is 830 WINTER ST, WALTHAM MA, 02451. ImmunoGen can also be reached via phone at (781) 895-0600 and via email at [email protected]. Learn More on Theresa Wingrove's contact information.
Has Theresa Wingrove been buying or selling shares of ImmunoGen?: Theresa Wingrove has not been actively trading shares of ImmunoGen during the last ninety days. Most recently, Theresa Wingrove sold 187,667 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $29.64, for a transaction totalling $5,562,449.88. Following the completion of the sale, the senior vice president now directly owns 3,426 shares of the company's stock, valued at $101,546.64. Learn More on Theresa Wingrove's trading history.
Who are ImmunoGen's active insiders?: ImmunoGen's insider roster includes Susan Altschuller (Sr. VP & CFO ), Stacy Coen (SVP), Mark Enyedy (Pres), Mark Enyedy (CEO), Renee Lentini (Insider), Kristine Peterson (Director), and Theresa Wingrove (SVP). Learn More on ImmunoGen's active insiders.
Are insiders buying or selling shares of ImmunoGen?: During the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 2,559,547 shares worth more than $45,624,932.36. The most recent insider tranaction occured on January, 16th when SVP Theresa Wingrove sold 187,667 shares worth more than $5,562,449.88. Insiders at ImmunoGen own 5.1% of the company. Learn More about insider trades at ImmunoGen.
Information on this page was last updated on 1/16/2024.

Theresa Wingrove Insider Trading History at ImmunoGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2024	Sell	187,667	$29.64	$5,562,449.88	3,426
12/15/2023	Sell	117,445	$29.40	$3,452,883.00	2,811
11/29/2023	Sell	6,792	$16.66	$113,154.72	2,811
11/15/2023	Sell	166,725	$15.85	$2,642,591.25	2,811
11/7/2023	Sell	19,517	$16.66	$325,153.22	2,811
10/16/2023	Sell	192,004	$14.40	$2,764,857.60	2,811
9/15/2023	Sell	192,013	$15.44	$2,964,680.72	2,811
1/10/2014	Sell	6,250	$15.04	$94,000.00

Theresa Wingrove Buying and Selling Activity at ImmunoGen

ImmunoGen Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Today's Range

Now: $31.23

$31.23

50 Day Range

MA: $31.23

$31.23

2 Week Range

Now: $31.23

$3.61

$31.25

Volume

40 shs

Average Volume

8,778,325 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

The Gold Grab of the Century

From Colonial Metals | Ad

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

Theresa Wingrove Biography and Net Worth

What is Theresa Wingrove's net worth?

How old is Theresa Wingrove?

What is Theresa Wingrove's salary?

How do I contact Theresa Wingrove?

Has Theresa Wingrove been buying or selling shares of ImmunoGen?

Who are ImmunoGen's active insiders?

Are insiders buying or selling shares of ImmunoGen?